What’s somewhat worrying though is there is no s

Quote:

---

What’s somewhat worrying though is there is no share price appreciation. The strategy isn’t working and has not been working for quite some time now. Nevertheless NP continues following this path hoping for the market to see the disparity between share price and value.

---

What could do it is a widespread preliminary release of actual clinical results in mTNBC. The faster we can get patients enrolled for that the better. By that time we will also be closer to FDA approval. What spikes share prices is fear of missing out. If we can hit the news big time FOMO will be overwhelming.

Quote:

---

Our most recent -ready to be signed- deal has fantastic terms, but is on hold as there might be even better .

---

Hopefully Tuesday we'll learn the background on that. It could be another offer came in, the terms were changed or the terms would place such bad limitations on us it would hinder other developments. If we don't get an answer I will be quite disappointed.

Quote:

---

The underlying problem (anything less than optimal isn’t good enough for NP) worries me. While thinking he’s doing the right thing he’s factually decreasing value as we need to dilute at continous lower prices.

---

Deal or no deal there would be dilution. Just less dilution with a deal because the share price should have seen an increase. If our new PR company does a proper job that may be accomplished anyway. Let's see if we can get Nader on Good Morning America or The View.